We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Invited Commentary |

A Call for Accurate Pharmacogenetic Labeling Telling It Like It Is

Wylie Burke, MD, PhD1; Kenneth Thummel, PhD2
[+] Author Affiliations
1Department of Bioethics and Humanities, School of Medicine, University of Washington, Seattle
2Department of Pharmaceutics, School of Pharmacy, University of Washington, Seattle
JAMA Intern Med. 2014;174(12):1945-1946. doi:10.1001/jamainternmed.2014.3276.
Text Size: A A A
Published online


Individual differences in response to medications are an important challenge in clinical practice. Drugs that work well for some patients are ineffective for others, and individuals vary markedly in their experience of adverse drug reactions. Some of this variation is associated with individual differences in the genes involved in drug uptake, distribution, metabolism, target engagement, and action. For example, individuals with the HLA-B*5701 variant have an almost 50% risk of a hypersensitivity reaction when exposed to the drug abacavir, used to treat human immunodeficiency virus infection; this adverse reaction is not seen with the use of an alternative drug in these individuals.1 The drug ivacaftor, used to treat cystic fibrosis, illustrates a different effect. This drug has genetically targeted efficacy; it binds to a defective transmembrane chloride channel protein present in a subset of patients with cystic fibrosis with a particular CFTR gene mutation (G551D), eliciting a structural change that enhances function.2 As these examples illustrate, pharmacogenetic testing offers great promise for improving the safety and efficacy of drug treatment.

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview





Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

See Also...
Articles Related By Topic
Related Collections
PubMed Articles